Stroke remains a leading cause of morbidity worldwide, with limited pharmacological options beyond thrombolysis and thrombectomy in the acute phase. Granulocyte colony-stimulating factor (G-CSF), a ...

Value-based programs, such as the Oncology Care Model (OCM), seek to improve care for patients undergoing chemotherapy, while reducing total costs. The purpose of this study is to quantify the impact ...

Granulocyte colony-stimulating factor (G-CSF) is routinely administered to prevent or treat chemotherapy-induced neutropenia by promoting neutrophil proliferation and differentiation. While generally ...

Purpose. The efficacy and safety of granulocyte colony-stimulating factor (G-CSF) in critically ill patients with severe sepsis or septic shock were evaluated. Summary. The medical literature was ...

Correlation of PI3K upregulation with NOTCH2 mutations in ibrutinib-resistant mantle cell lymphoma. This is an ASCO Meeting Abstract from the 2020 ASCO Annual Meeting I. This abstract does not include ...

Limitations and other factors to consider when utilizing granulocyte colony-stimulating factors as prophylaxis for chemotherapy-induced neutropenia. Lee Schwartzberg, MD, FACP: While ...

The effects of sargramostim and filgrastim on hematopoietic cells are described. Filgrastim is a lineage-specific colonystimulating factor (CSF), mainly affecting neutrophils. In addition to enhancing ...

A historical overview regarding the development and role of granulocyte colony-stimulating factors as prophylaxis for chemotherapy-induced neutropenia and recommendations for use. Lee Schwartzberg, MD ...

Please provide your email address to receive an email when new articles are posted on . In certain settings. Whether a patient has cancer or not, we are trained to reach into our toolbox for whatever ...

A pilot study has suggested that intense physical exercise may mobilise a smaller but more targeted population of blood stem cells than granulocyte colony-stimulating factor, the standard drug ...